AXSM: Axsome Therapeutics, Inc.
2022-08-19 Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
The MACD is curling and AXSM has a gap to fill in the $51 range. The most recent candle closed above the .61 fib level after price consolidation in the $39 range.
$38.52 seems like a reasonable support level.
Targeting: $43.34, $46.94, $51
Every trader worth their salt needs to trade in at least one crappy biotech.
I say trade, but chances are you will end up an investor... just like those guys who bought at $100.
AXSM has a very nice pipeline. The drop was due to incorrect FDA filing. Perhaps the clean up their act and release some drugs for all the kids (and elderly) to enjoy.
I'm going to post all the stocks my dowsing is giving and see how these shake out. I have this as moving back down immediately. This name needs some kinda therapy to recover from this destruction!
My reading suggests it moves down about 14-15%. We'll see.
Bad news but good technical levels, thinking an amazing bullish opp setting up. Using 30 as the key level and adding on each whole number on the way up. 35 a key level as well and 200 sitting at 37 ish
Hello traders, I see a potential short term bullish stock setup. We are in 2 nice bullish flag pattern and testing support area. If we get a nice rejection from 46-47 area and broke the minor bullish flag pattern. It's possible to push upside around 57. Our expectation is %21 return in short time while we risking just %7. Nice risk reward ratio 1-3.
AXSM is wound up tight as can be and should be ready to move somewhere soon. .616 FIB level have been support inside a tightening range. Watch the 3 day closure as it is making a strong bullish hammer off the EMA's and the .618 FIB level.
Monthly Volume is following PA nicely and EMA's are catching up. Burning the clock in bullish context with bullish PA,...
Another perfect bubble pattern presents itself. By comparison APHA overlayed in yellow shows how similar and easy to recognize the pattern is. The only difference between the two is APHA happened about 2 years earlier (2017 vs. 2019)
Whether the fundamentals stack up or not, the pattern is remarkably similar to other recent bubbles (last 2 years).
AXSM clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system, it is accelerating the completion of the ADVANCE-1 Phase 2/3 trial of AXS-05 in patients with Alzheimer’s disease agitation to ensure the safety of this vulnerable patient population during the COVID-19 pandemic. i expect that this end of the...